Lonza confirms full-year outlook
23/10/2025 05:48
Oct 23 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business. The Basel-based company continues to expect a core earnings before interest, taxes, depreciation and amortization margin of 30% to 31% for the CDMO business in 2025. (Reporting by Marleen Kaesebier in Gdansk; editing by Milla Nissi-Prussak) ((marleen.kaesebier@thomsonreuters.com;))
Recent news on Lonza AG
See all newsLonza buys 5 sites from Germany's Merck to more than double US footprint (updated)
Brief: Merck KGaA Confirms Divestment Of CDMO Business To Lonza
Lonza agrees to buy five US sites from Merck KGaA
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September